ACQUIRED IMMUNODEFICIENCY SYNDROME AMONG PATIENTS ATTENDING HEMOPHILIA TREATMENT CENTERS AND MORTALITY EXPERIENCE OF HEMOPHILIACS IN THE UNITED STATES

Robert E. Johnson(Centers for Disease Control and Prevention), Charles J. Carman, James W. Curran(Centers for Disease Control and Prevention), Louis M. Aledort(Icahn School of Medicine at Mount Sinai), Dale N. Lawrence(Centers for Disease Control and Prevention), Alan P. Brownstein, Bruce L. Evatt(National Institutes of Health), Dennis J. Bregman(Centers for Disease Control and Prevention), Lawrence D. Zyla(Centers for Disease Control and Prevention), M. Elaine Eyster(National Cancer Institute)
American Journal of Epidemiology
June 1, 1985
10.1093/oxfordjournals.aje.a114051
Cited by 67

Related Papers

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.
|PubMed|2001|803
Definitions in Hemophilia
|Thrombosis and Haemostasis|2001|772
A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs
|Journal of Internal Medicine|1994|613
A More Uniform Measurement of Factor VIII Inhibitors
|Thrombosis and Haemostasis|1975|587